Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study.

I, Schreiber; M, Buchfelder; M, Droste; K, Forssmann; K, Mann; B, Saller; CJ, Strasburger

doi:10.1530/eje.1.02312

Public

Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study.

Shared by NobleBlocks on Jan 1, 2007 • 12:00 AM UTC

Authors:

Schreiber I

Buchfelder M

Droste M

Abstract

<h4>Objective</h4>The GH receptor antagonist pegvisomant is a highly effective new treatment option in acromegaly. The German Pegvisomant Observational Study (GPOS) was started to monitor long-term safety and efficacy of pegvisomant as prescribed in clinical practice.<h4>Design</h4>GPOS is an observ...

Discussions